ChemAbout

ChemAbout is a B2B platform where chemical buyers and suppliers discover each other.

Post a purchase requestList your products (for suppliers)
© 2026 ChemAbout
Compound Index|Demand Board|Insights|Exhibitions|Compliance|Help Center|Privacy Policy|Terms of Service|[email protected]
Home/Compounds/Pharmaceutical Intermediate/Vc-MMAD
C70H104N12O14S
1369.7 g/mol
Pharmaceutical Intermediate

Vc-MMAD

CAS1401963-17-4
Category
Pharmaceutical Intermediate
Compound Class
Peptide
Primary Use
Pharmaceutical Intermediate

Vc-MMAD is a complex chemical compound used as a linker-payload in antibody-drug conjugates (ADCs). Its structure includes multiple amide groups, ether linkages, and ring systems, designed to connect an antibody to a cytotoxic agent.

Antibody-drug conjugate linker-payloadPharmaceutical intermediate for ADC manufacturingResearch compound for targeted drug delivery studies

Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.

Sourcing Vc-MMAD?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request→Supplier? List your product for this CAS→

Related Compounds

StrongStructure SimilarSimilarity 0.86

MC-Val-Cit-PAB-MMAF

CAS863971-17-9

pharmaceutical raw material

ReferenceSame Category

Ticagrelor Impurity 202

CAS1402150-27-9

pharmaceutical intermediate

ReferenceSame Category

(1R,2S)-2-(3,4-Difluorophenyl)cyclopropanamine hydrochloride

CAS1402222-66-5

pharmaceutical intermediate

ReferenceSame Category

Methyl 5-bromo-2-methyl-3-((tetrahydro-2H-pyran-4-yl)amino)benzoate

CAS1403257-49-7

pharmaceutical intermediate

ReferenceSame Category

1-[[2'-(2,5-Dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-1H-benzimidazole-7-carboxylic acid ethyl ester

CAS1403474-70-3

pharmaceutical intermediate

Related Reading

Therapeutic Peptides in 2026: This Year's Breakthroughs

2026 has been a concentrated year for peptide therapeutics. Efficacy reached a new high in late-stage trials, the obesity field moved beyond the incretins to amylin, the oral route reached weight management, and peptide-guided radioligand therapy kept advancing — each point tied to a specific 2025–2026 result.

Read more
Identifiers
IUPAC Name

[4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate

InChIKey

GRBICHHPFYWKKI-BDVWXETGSA-N

SMILES

CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@@H](C)C(=O)N[C@@H](CC2=CC=CC=C2)C3=NC=CS3)OC)OC)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(C)C(=O)OCC4=CC=C(C=C4)NC(=O)[C@H](CCCNC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)CCCCCN5C(=O)C=CC5=O

Synonyms (4)
  • Vc-MMAD
  • mc-Val-Cit-PABC-MMAD

Sourcing Vc-MMAD?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request→Supplier? List your product for this CAS→